The Childhood Cancer & Blood Disorders group at VHIR is composed of clinical, translational, and basic researchers and has three laboratories (Sarcomas lab, Neural Tumors lab, and Rare Anemia Disorders lab) and three research programs (Personalized Medicine, Clinical Trials Unit, and Stem Cell & Advanced Therapies Hematological Malignancies & Cell Therapy).
Pediatric cancer has specific features that define it as an entity that, in the majority of cases, is certainly different from adult tumors; i.e., etiology, biology, response to treatment, and prognosis are significantly different.
The implementation of multimodal treatments (i.e., combinations of chemotherapies, radiotherapies, biological agents) in the last 20 years has enabled the increase in patient survival to around 80%.
Although the global survival of pediatric cancer is around 80%, patients with some types of tumors present a much lower survival.
Moreover, almost two-thirds of patients who survive suffer severe side effects due to the treatment.
Therefore, the development of therapies to treat the 20% of patients who do not survive and to reduce the toxicity of current treatments, avoiding long-term side effects, is extremely necessary.
The main objective of the Neural Tumor Laboratory is to implement the use of epigenetic therapies, that is, therapies against gene expression modulators that, in turn, regulate several genes, pathways, or cellular processes, without affecting the DNA sequence.
The laboratory focuses on neuroblastoma, a pediatric solid tumor of the peripheral nervous system, and on pediatric brain tumors of the central nervous system such as ependymoma, medulloblastoma, or high-grade glioma, among others (More information: Neural Tumors Lab ).
Education and Qualifications: Required: Bachelor's Degree in Sciences (Biology, Biochemistry, Pharmacy, Biotechnology, Genetics, Medicine, etc.)
and Master.
PhD in Cancer Biology.
Desired: Good command of Spanish & English (C1/C2 level).
Experience and Knowledge: Required: Experience in drug development projects.
Desired: Good communication skills and good team player.
International internship.
Main Responsibilities and Duties: Full-time position: 40h/week.
In vitro and In vivo drug screening and efficacy studies.
Prepare presentation of results and communication/dissemination material.
Participation in laboratory outreach activities.
Labour Conditions: Starting date: February 2025.
Gross annual salary: Remuneration will depend on experience and skills.
Salary ranges are consistent with our Collective Agreement pay scale.
Contract: Technical and scientific activities contract linked to the project activities.
What Can We Offer?
Incorporation to Vall d'Hebron Research Institute (VHIR), a public sector institution that promotes and develops biomedical research, innovation, and teaching at Vall d'Hebron University Hospital (HUVH), the biggest hospital in Barcelona and the largest of the Catalan Institute of Health (ICS).
A scientific environment of excellence, highly dynamic, where high-end biomedical projects are continuously developed.
Continuous learning and a wide range of responsibilities within a stimulating work environment.
Individual training opportunities.
Flexible working hours.
23 days of holidays + 9 personal days.
Flexible Remuneration Program (including dining checks, health insurance, transportation, and more).
Corporate Benefits platform through which you can obtain significant discounts on travel, culture, technology, gastronomy, sports, among many others.
Healthy Offering: choose from a variety of wellbeing-focused activities to be the healthiest you.
Deadline to apply: 26-12-2024.
VHIR embraces Equality and Diversity.
As reflected in our values, we work toward ensuring inclusion and equal opportunity in recruitment, hiring, training, and management for all staff within the organization, regardless of gender, civil status, family status, sexual orientation, gender identity and expression, religion, age, functional diversity, or ethnicity.
#J-18808-Ljbffr